DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

Recruiting now · Phase 1

Conditions studied: Fibrolamellar Hepatocellular Carcinoma (FLC)

In brief

The primary objective of the trial is the safety and tolerability of administering a vaccine targeting the DNAJB1-PRKACA fusion kinase, in combination with nivolumab and ipilimumab in patients with unresectable or metastatic FLC and with non-FLC solid tumors and to assess the T-cell response.

Key facts

Study ID
NCT04248569
Run by
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
People needed
56
Starts
2020-04-20
Expected to finish
2034-03-01
Last updated by the study team
2025-12-03

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.